Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
231 Leser
Artikel bewerten:
(1)

Prostate Cancer Treatment Market to Reach $9.90 Billion, Globally, by 2026 at 4.6% CAGR: Allied Market Research

Increase in incidence of prostate cancer, rise in geriatric population, and surge in government expenditure on the healthcare industry drive the growth of the global prostate cancer treatment market

PORTLAND, Oregon, Feb. 12, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Prostate Cancer Treatment Market by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026." As per the report, the global prostate cancer treatment industry was estimated at $6.88 billion in 2018 and is expected to reach $9.90 billion by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Allied_Market_Research_Logo

Drivers, restraints, and opportunities-

Rise in prevalence of prostate cancer, increase in geriatric population, and upsurge in government expenditure on the healthcare industry fuel the growth of the global prostate cancer treatment market. On the other hand, adverse effects associated with the use of prostate cancer treatment drugs restrain the growth to some extent. However, development in emerging markets is expected to create an array of opportunities for the key players in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2653

The hormone therapy segment to maintain its leadership status till 2026-

Based on drug type, the hormone therapy segment accounted for nearly half of the global prostate cancer treatment market share in 2018, and is expected to dominate during 2019-2026. Increase in demand for hormone therapy drugs, rise in patient awareness regarding hormone therapy treatment for prostate cancer, promising pipeline drugs, and evolving methods of prostate cancer treatment drive the growth of the segment. At the same time, the biological therapy segment would grow at the fastest CAGR of 5.5% by the end of 2026. Increase in public health awareness resulting into early disease diagnosis and treatment, rise in incidence of prostate cancer, and top-end technological advancements in drug development along with promising pipeline products boost the growth of the segment

The hospital pharmacy segment to rule the roost during the estimated period-

Based on distribution channel, the hospital pharmacy segment held the largest share in 2018, generating nearly three-fifths of the global prostate cancer treatment market. This is due to surge in number of hospitalized prostate cancer treatment patients, increase in number of hospital pharmacies, and development in the structure of hospital pharmacies. The online pharmacy segment, on the other hand, would cite the fastest CAGR of 6.4% during the study period. This is attributed to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacy, and surge in number of internet users.

North America to maintain its dominance throughout the forecast period-

Based on geography, North America contributed to nearly half of the global prostate cancer treatment market revenue in 2018, and is projected to maintain the lion's share till 2026. Presence of advanced healthcare facilities with trained medical professionals, and rise in number of R&D centers in this region have fueled the growth. Simultaneously, the region across Asia-Pacific is anticipated to register the fastest CAGR of 6.6% by 2026. Surge in healthcare reforms, and technological advancements in the field of healthcare in this province have propelled the growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2653

Key market players:

  • Priceline Group
  • Travel Leaders Group
  • Expedia Group
  • World Travel, Inc.
  • JTB Americas Group
  • American Express Travel
  • Cox & Kings Ltd.
  • Carlson Wagonlit Travel
  • TUI Group.
  • Thomas Cook (India) Limited

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information:https://www.alliedmarketresearch.com/library-access

Similar Reports:

Cancer Immunotherapy Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Cancer Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2019-2026

Top 10 Cancer Drugs Market: Opportunity Analysis and Industry Forecast, 2019-2026

Artificial Intelligence in Drug Screening Market: Opportunity Analysis and Industry Forecast, 2019-2026

Drug Discovery Services Market: Global Opportunity Analysis and Industry Forecast, 2019-2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Life Science Market:https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

© 2020 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.